{"type":"trials","record":{"id":41841,"source_id":"clinicaltrials-gov","external_id":"NCT03815825","title":"GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)","brief_summary":"Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Ionis Pharmaceuticals, Inc.","enrollment":332,"countries":["United States","Australia","Austria","Canada","Czechia","Netherlands","New Zealand","Poland","Spain"],"start_date":"2019-03-04","completion_date":"2024-06-12","last_update_date":"2025-03-07","source_url":"https://clinicaltrials.gov/study/NCT03815825","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Ionis Pharmaceuticals, Inc.","interventions":["IONIS-FB-LRx","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Rate of Change from Baseline in the Geographic Atrophy (GA) Area at Week 49, as Assessed by Retinal Imaging — Week 49","Absolute change in the GA area from Baseline as measured by Fundus Autofluorescence (FAF) — Baseline and up to Week 57","Percentage Change from Baseline in Levels of Factor B (FB) in Plasma — Baseline and up to Week 49","Percentage Change from Baseline in Levels of Serum AH50 Activity — Baseline and up to Week 49","Absolute Change from Baseline in Low Luminance Visual Acuity (LLVA) — Baseline and up to Week 49"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Macular Degeneration","Geographic Atrophy","IONIS-FB-LRx","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03815825","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-03-04 to 2024-06-12","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.879Z","intervention":["IONIS-FB-LRx","Placebo"],"participants":332,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Rate of Change from Baseline in the Geographic Atrophy (GA) Area at Week 49, as Assessed by Retinal Imaging — Week 49","Absolute change in the GA area from Baseline as measured by Fundus Autofluorescence (FAF) — Baseline and up to Week 57","Percentage Change from Baseline in Levels of Factor B (FB) in Plasma — Baseline and up to Week 49","Percentage Change from Baseline in Levels of Serum AH50 Activity — Baseline and up to Week 49","Absolute Change from Baseline in Low Luminance Visual Acuity (LLVA) — Baseline and up to Week 49"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41841","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}